Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation develops and markets less invasive medical devices and therapies used by healthcare professionals and institutions globally. News about BSX centers on operating results, business highlights, capital-structure updates and product developments across cardiovascular, respiratory, digestive, oncological, neurological and urological care.
Recurring company updates include clinical evidence and regulatory milestones for platforms such as FARAPULSE pulsed field ablation, WATCHMAN left atrial appendage closure, EKOS endovascular therapy and the Asurys Fluid Management System. Coverage also reflects conference presentations, FDA clearances, trial results and management discussions of quarterly performance across the company’s medical-technology portfolio.
Boston Scientific (NYSE: BSX) reported that the randomized HI-PEITHO trial met its primary endpoint: EKOS plus anticoagulation was superior to anticoagulation alone for intermediate-risk pulmonary embolism (4.0% vs. 10.3%; P=0.005), a 61% relative reduction in events.
Trial enrolled 544 patients across 59 U.S. and European sites; no intracranial bleeding through 30 days; patients will be followed to one year.
Boston Scientific (NYSE: BSX) will host an investor event and live webcast on March 28, 2026 at 6:30 p.m. ET / 5:30 p.m. CT to discuss key clinical data presented at the 75th Annual Scientific Session of the American College of Cardiology.
The event will feature Dr. Kenneth Stein, Dr. Brad Sutton, and Dr. Michael R. Jaff. The live webcast and replay will be accessible at https://investors.bostonscientific.com, with replay available about one hour after the event ends.
Penumbra (NYSE: PEN) reported fourth-quarter 2025 revenue of $385.4M (+22.1%) and full-year 2025 revenue of $1,403.7M (+17.5%). Gross margin improved to 68.0% in Q4 and 67.1% for FY2025. Income from operations was $59.2M in Q4 and $189.2M for FY2025. Net income for Q4 was $47.3M and FY net income was $177.7M. The company will not provide 2026 guidance or host an earnings call due to the proposed acquisition by Boston Scientific (NYSE: BSX).
Boston Scientific (NYSE: BSX) elected Cathy Smith and Christophe Weber to its Board of Directors, effective Feb 18, 2026.
Smith brings senior finance and operational experience as current CFO of Starbucks and former CFO roles at major retailers; Weber adds global pharmaceutical and CEO leadership from Takeda. Their elections follow announced retirements of John Sununu and Yoshiaki Fujimori, who will not stand for re-election at the 2026 annual meeting.
Boston Scientific (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and CEO, and Kenneth Stein, M.D., senior VP and global chief medical officer, will join a 30-minute Q&A at ~9:10 a.m. ET.
A live webcast and replay will be available at the company investor website, with the replay posted about one hour after the session ends.
Boston Scientific (NYSE: BSX) reported strong fourth-quarter 2025 results with Q4 net sales of $5.286 billion (+15.9% reported, +12.7% organic) and GAAP EPS of $0.45 (adjusted EPS $0.80). For full-year 2025, net sales were $20.074 billion (+19.9% reported) and adjusted EPS was $3.06. The company provided 2026 guidance of ~10.5–11.5% reported net sales growth and adjusted EPS of $3.43–3.49. Key developments include FDA/CE approvals for FARAPOINT PFA catheter, launches of SEISMIQ IVL and TheraSphere 360 clearance, enrollment and trial progress across AF, SCS and LAA closure studies, announced acquisitions of Penumbra and Valencia Technologies, and completion of the Nalu Medical acquisition.
Boston Scientific (NYSE: BSX) agreed to acquire Penumbra (NYSE: PEN) in a cash-and-stock deal valuing Penumbra at $374 per share, implying an enterprise value of about $14.5 billion. Consideration is ~73% cash and ~27% stock, with a 3.8721 BSX share election per PEN share. Penumbra expects 2025 reported revenue of ~$1.4 billion (growth ~17.3%–17.5%) and Q4 growth ~21.4%–22.0%. Boston Scientific plans to finance roughly $11 billion of the cash portion with cash on hand and new debt. The deal is expected to close in 2026, subject to approvals, and to be mildly dilutive to adjusted EPS by $0.06–0.08 in year one, turning neutral/acc-retive thereafter.
Boston Scientific (NYSE: BSX) agreed to acquire Valencia Technologies to add the eCoin implantable tibial nerve stimulation (ITNS) system for urge urinary incontinence (UUI). The eCoin device is FDA-approved (2022) and showed a 68% responder rate (>=50% UUI reduction) in the pivotal trial. Boston Scientific said the deal is expected to close in H1 2026, will expand its urology and pelvic health portfolio, and aims to broaden minimally invasive treatment options for overactive bladder. The company expects an immaterial impact on adjusted EPS in 2026 but greater GAAP dilution from acquisition-related charges and amortization; transaction terms were not disclosed.
Boston Scientific (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 with a 40-minute Q&A starting at approximately 9:00 a.m. PT / 12:00 p.m. ET. Presenters include Mike Mahoney (chairman & CEO), Jon Monson (EVP & CFO) and Ken Stein, M.D. (SVP & global chief medical officer).
The company will also host a webcast conference call to discuss fourth quarter and full year results for the period ended December 31, 2025 on February 4, 2026 at 8:00 a.m. ET, preceded by a news release. Live webcasts and replays will be available at https://investors.bostonscientific.com, with replays posted about one hour after each event.
CathVision (BSX) announced two milestones on Dec 10, 2025: the appointment of Eric Thepaut as independent Chairman of the Board and the commercial release of ECGenius System Version 3.5.
Thepaut joins after retirement from Boston Scientific, bringing commercial and integration experience. CathVision said ECGenius and Cardialytics were FDA-cleared in 2023 and ECGenius received CE mark in 2025. Version 3.5 adds user interface flexibility, DICOM archiving, hospital worklist integration, hardware refinements to reduce post-pacing artifacts, and streamlined 12-lead ECG capture.